Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

Older adults with advanced kidney disease are often motivated to receive a transplant but may face emotional and psychosocial ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The burden is particularly high in urban areas, where the prevalence reaches 15.2 percent compared to just 2.0 percent in ...

Massachusetts General Hospital has performed its second successful genetically edited pig kidney transplant into a patient, MGH reported on Friday. The “miracle” transplant is giving 66-year-old Tim ...

Genetically modified pig kidneys begin trials for 50 U.S. kidney failure patients FDA launches clinical trials for organ ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...